Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 42Uterine Cervical Neoplasms 41Breast Neoplasms 10Vaginal Neoplasms 6Neoplasms 6Endometrial Neoplasms 6Liver Neoplasms 5Uterine Neoplasms 4Sarcoma 4Lung Neoplasms 4Esophageal Neoplasms 4Vulvar Neoplasms 3Retinoblastoma 3Radiation Injuries 3Ovarian Neoplasms 3Hyperthermia 3Carcinoma, Hepatocellular 3Adenocarcinoma 3Rhabdomyosarcoma 2Rectal Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Gynecologic Cancer 2Desmoplastic Small Round Cell Tumor 2Deglutition Disorders 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Ductal, Breast 2Breast Carcinoma In Situ 2Uveal Melanoma 1

Interventions

tremelimumab 1durvalumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Immunoglobulin G 1Disulfides 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Malignant Female Reproductive System Neoplasm × Brachytherapy × Clear all
NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡